Internal Medicine · El Paso, TX
NPI
1073827762
Since 2010
Specialty
Internal Medicine
Code 207R00000X
Group practices
4
Medicare group memberships
Hospitals
4
Hospital affiliations
106 Mesa Park Dr Ste 200
El Paso, TX, 79912
Phone (915) 300-3484
Groups this clinician bills Medicare through
Medicare paid, 2024
$132K
2,027 services
Medicare patients, 2024
227
Average age 74
Drug cost, 2024
$2.0M
14,123 prescriptions
Company payments, 2025
$1,970
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Pablo A Casares was code 99308 (snf e&m), 1,103 times for 42 patients. In total Pablo A Casares billed 2,027 services in 23 codes, and Medicare paid $132K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-10-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99308 SNF E&M | Facility | 1,103 | 42 | $55.07 | $61K |
| 99214 Office E&M - Established | Office | 309 | 125 | $75.02 | $23K |
| 99232 Hospital E&M - Subsequent | Facility | 243 | 44 | $58.54 | $14K |
| 99223 Hospital E&M - Initial | Facility | 61 | 47 | $119.82 | $7,309 |
| 99239 Hospital Discharge Management | Facility | 48 | 40 | $86.42 | $4,148 |
| 99497 Care Management/Coordination | Office | 38 | 38 | $53.58 | $2,036 |
| 99306 SNF E&M | Facility | 31 | 29 | $124.99 | $3,875 |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 28 | 28 | $123.79 | $3,466 |
| 99233 Hospital E&M - Subsequent | Facility | 21 | 19 | $85.21 | $1,789 |
| G0438 Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 14 | 14 | $157.45 | $2,204 |
| 99203 Office E&M - New | Office | 13 | 13 | $77.91 | $1,013 |
By year: 2022 $119K for 1,560 services; 2023 $269K for 4,042 services; 2024 $132K for 2,027 services.
Medicare prescription drug claims, 2024
In 2024, the drug Pablo A Casares prescribed most often to Medicare patients was Atorvastatin Calcium, with 854 prescriptions and refills. In total Pablo A Casares wrote 14,123 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 854 | 2,358 | 294 | $5,695 |
| Levothyroxine Sodium Generic | 574 | 1,495 | 162 | $4,510 |
| Metformin Hcl Generic | 533 | 1,449 | 170 | $2,686 |
| Lisinopril Generic | 513 | 1,444 | 167 | $2,750 |
| Gabapentin Generic | 442 | 1,132 | 164 | $10K |
| Amlodipine Besylate Generic | 401 | 1,059 | 135 | $1,726 |
| Losartan Potassium Generic | 358 | 948 | 120 | $2,519 |
| Pantoprazole Sodium Generic | 355 | 910 | 145 | $2,500 |
| Tamsulosin Hcl Generic | 319 | 798 | 102 | $2,498 |
| Carvedilol Generic | 237 | 578 | 86 | $1,462 |
| Omeprazole Generic | 235 | 667 | 79 | $4,949 |
| Fluticasone Propionate Generic | 231 | 497 | 115 | $4,001 |
| Simvastatin Generic | 216 | 572 | 64 | $1,444 |
| Metoprolol Succinate Generic | 189 | 514 | 71 | $1,442 |
| Ibuprofen Generic | 186 | 481 | 87 | $5,695 |
Brand drugs: 1,984 claims; generic drugs: 11,946 claims; opioid claims: 90.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Pablo A Casares $1,970 ($1,970 in general payments such as food, travel and fees) from 17 companies. The largest payer was Abbvie Inc. with $1,099.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 56 | $1,099 |
| Amgen Inc. AMGN | 11 | $212 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $181 |
| UCB, Inc. UCB.BR | 5 | $122 |
| Madrigal Pharmaceuticals MDGL | 3 | $88.19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39.27 |
| Radius Health, Inc. | 2 | $32.78 |
| Novo Nordisk Inc NVO | 1 | $27.05 |
| Abbott Laboratories ABT | 1 | $24.59 |
| Tactile Systems Technology Inc TCMD | 1 | $22.84 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.